liothyronine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1585 6893-02-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • liothyronine
  • liothyronine sodium
  • triiodothyronine
  • liothyronin
A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
  • Molecular weight: 650.98
  • Formula: C15H12I3NO4
  • CLOGP: 2.33
  • LIPINSKI: 1
  • HAC: 5
  • HDO: 3
  • TPSA: 92.78
  • ALOGS: -4.52
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
60 mcg O
60 mcg P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.00 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ
S (Water solubility) 0.01 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
May 8, 1956 FDA KING PHARMS R AND D

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sensitisation 487.15 14.92 120 14315 3266 63471321
Polycystic ovaries 458.82 14.92 121 14314 4350 63470237
Ejection fraction 390.63 14.92 94 14341 2312 63472275
Rhinitis allergic 347.61 14.92 122 14313 11605 63462982
Blood test abnormal 316.99 14.92 123 14312 15506 63459081
Hypothyroidism 310.39 14.92 164 14271 42468 63432119
Sleep disorder due to a general medical condition 301.80 14.92 111 14324 12077 63462510
Carpal tunnel syndrome 296.04 14.92 127 14308 20690 63453897
Sleep apnoea syndrome 288.27 14.92 138 14297 28995 63445592
Burning sensation 222.43 14.92 144 14291 54263 63420324
Cardiac disorder 208.95 14.92 135 14300 50681 63423906
Renal disorder 204.16 14.92 114 14321 32860 63441727
Ejection fraction abnormal 176.82 14.92 47 14388 1738 63472849
Fibromyalgia 161.74 14.92 139 14296 80281 63394306
Nephrectomy 160.34 14.92 42 14393 1466 63473121
Gastrooesophageal reflux disease 160.07 14.92 149 14286 95490 63379097
Asthma 151.51 14.92 165 14270 127396 63347191
Loss of personal independence in daily activities 128.13 14.92 133 14302 97157 63377430
Therapeutic product effect incomplete 120.14 14.92 145 14290 124911 63349676
Hypertension 75.76 14.92 184 14251 279119 63195468
Wheezing 70.02 14.92 97 14338 95498 63379089
Headache 66.57 14.92 302 14133 632939 62841648
Full blood count abnormal 48.37 14.92 47 14388 31670 63442917
Urine chloride decreased 39.34 14.92 8 14427 87 63474500
Hyperthyroidism 39.25 14.92 30 14405 14643 63459944
Hospitalisation 35.66 14.92 67 14368 85014 63389573
Suicidal ideation 35.12 14.92 56 14379 62365 63412222
Urine sodium decreased 34.66 14.92 8 14427 163 63474424
Thyroid function test abnormal 32.20 14.92 16 14419 3631 63470956
Drug intolerance 32.14 14.92 15 14420 308646 63165941
Systemic lupus erythematosus 31.31 14.92 5 14430 208913 63265674
Arthropathy 30.27 14.92 8 14427 234784 63239803
Glossodynia 29.90 14.92 3 14432 178873 63295714
Product substitution issue 28.80 14.92 26 14409 15970 63458617
Myopathy 28.02 14.92 22 14413 11169 63463418
Maternal exposure during pregnancy 27.43 14.92 8 14427 220054 63254533
Acute kidney injury 27.11 14.92 13 14422 263402 63211185
Palpitations 27.03 14.92 71 14364 112699 63361888
Wound 26.61 14.92 3 14432 163260 63311327
Weight increased 26.19 14.92 123 14312 260669 63213918
Feeling abnormal 22.02 14.92 79 14356 148313 63326274
Product dose omission issue 21.70 14.92 108 14327 234205 63240382
General physical health deterioration 20.62 14.92 10 14425 201392 63273195
Peak expiratory flow rate decreased 20.38 14.92 7 14428 622 63473965
Tri-iodothyronine increased 19.84 14.92 5 14430 149 63474438
Tri-iodothyronine decreased 19.84 14.92 5 14430 149 63474438
Thrombocytopenia 19.76 14.92 5 14430 151152 63323435
Product quality issue 18.57 14.92 31 14404 35834 63438753
Pre-existing condition improved 18.08 14.92 15 14420 8229 63466358
Blood thyroid stimulating hormone abnormal 18.06 14.92 7 14428 877 63473710
Blood thyroid stimulating hormone increased 17.70 14.92 14 14421 7180 63467407
Nail growth abnormal 17.41 14.92 6 14429 539 63474048
Nephropathy 17.04 14.92 13 14422 6328 63468259
Toxicity to various agents 16.65 14.92 19 14416 247231 63227356
Blood thyroid stimulating hormone decreased 15.96 14.92 11 14424 4579 63470008
Vascular parkinsonism 15.60 14.92 4 14431 128 63474459
Joint swelling 15.52 14.92 32 14403 327634 63146953
Dyspnoea 15.44 14.92 223 14212 661090 62813497

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Secondary hypogonadism 47.22 23.30 9 2017 293 34954612
Rhythm idioventricular 46.59 23.30 9 2017 315 34954590
Diffuse vasculitis 43.28 23.30 7 2019 85 34954820
Autoimmune thyroiditis 40.00 23.30 10 2016 1164 34953741
Thyrotoxic periodic paralysis 39.91 23.30 7 2019 142 34954763
Loose associations 38.54 23.30 6 2020 56 34954849
Performance enhancing product use 37.24 23.30 6 2020 71 34954834
Glucose tolerance decreased 37.08 23.30 6 2020 73 34954832
Sinus arrest 31.54 23.30 9 2017 1731 34953174
Feelings of worthlessness 28.72 23.30 6 2020 313 34954592
Pressure of speech 26.10 23.30 6 2020 489 34954416
Haematocrit increased 25.57 23.30 8 2018 2105 34952800
Insulin-like growth factor increased 25.12 23.30 7 2019 1236 34953669
Hyperthyroidism 24.35 23.30 12 2014 10554 34944351
Blood prolactin decreased 24.03 23.30 5 2021 256 34954649
Systolic hypertension 23.75 23.30 5 2021 271 34954634

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sensitisation 477.65 15.63 110 12683 3201 79728394
Polycystic ovaries 468.39 15.63 111 12682 3668 79727927
Ejection fraction 373.72 15.63 84 12709 2185 79729410
Rhinitis allergic 339.03 15.63 111 12682 12158 79719437
Carpal tunnel syndrome 306.59 15.63 116 12677 19412 79712183
Blood test abnormal 299.15 15.63 111 12682 17599 79713996
Sleep disorder due to a general medical condition 280.31 15.63 100 12693 14177 79717418
Hypothyroidism 274.23 15.63 144 12649 52248 79679347
Sleep apnoea syndrome 251.88 15.63 121 12672 36357 79695238
Burning sensation 221.38 15.63 130 12663 58502 79673093
Fibromyalgia 202.62 15.63 127 12666 64213 79667382
Cardiac disorder 192.62 15.63 124 12669 65633 79665962
Renal disorder 179.30 15.63 101 12692 42004 79689591
Ejection fraction abnormal 173.74 15.63 46 12747 2394 79729201
Gastrooesophageal reflux disease 166.32 15.63 136 12657 104110 79627485
Nephrectomy 160.79 15.63 42 12751 2073 79729522
Asthma 141.53 15.63 139 12654 134956 79596639
Loss of personal independence in daily activities 127.38 15.63 116 12677 102464 79629131
Therapeutic product effect incomplete 118.17 15.63 129 12664 141516 79590079
Hypertension 81.46 15.63 170 12623 330822 79400773
Headache 77.32 15.63 255 12538 653517 79078078
Wheezing 62.52 15.63 85 12708 116579 79615016
Hyperthyroidism 60.35 15.63 40 12753 22169 79709426
Urine chloride decreased 41.03 15.63 8 12785 101 79731494
Hospitalisation 36.53 15.63 59 12734 94177 79637418
Secondary hypogonadism 36.28 15.63 9 12784 360 79731235
Diffuse vasculitis 34.01 15.63 7 12786 118 79731477
Urine sodium decreased 33.28 15.63 8 12785 280 79731315
Thyrotoxic periodic paralysis 32.24 15.63 7 12786 154 79731441
Full blood count abnormal 32.19 15.63 36 12757 40438 79691157
Loose associations 32.14 15.63 6 12787 59 79731536
Rhythm idioventricular 31.59 15.63 9 12784 615 79730980
Glucose tolerance decreased 30.75 15.63 6 12787 76 79731519
Performance enhancing product use 30.26 15.63 6 12787 83 79731512
Tri-iodothyronine increased 28.99 15.63 7 12786 250 79731345
Insulin-like growth factor increased 28.83 15.63 11 12782 1875 79729720
Thrombocytopenia 26.90 15.63 5 12788 265254 79466341
Suicidal ideation 25.85 15.63 45 12748 76295 79655300
Blood thyroid stimulating hormone decreased 25.08 15.63 14 12779 5702 79725893
Feeling abnormal 24.20 15.63 68 12725 159131 79572464
Thyroid function test abnormal 23.45 15.63 11 12782 3123 79728472
Product dose omission issue 23.45 15.63 90 12703 247447 79484148
Myopathy 23.06 15.63 22 12771 20541 79711054
Acute kidney injury 22.79 15.63 30 12763 519374 79212221
Palpitations 20.15 15.63 55 12738 126555 79605040
Weight increased 20.14 15.63 93 12700 277293 79454302
Pyrexia 20.11 15.63 50 12743 678659 79052936
Product substitution issue 19.61 15.63 20 12773 20236 79711359
Feelings of worthlessness 19.39 15.63 6 12787 546 79731049
Anaemia 19.21 15.63 26 12767 444989 79286606
Toxicity to various agents 18.84 15.63 24 12769 421516 79310079
Nephropathy 18.27 15.63 14 12779 9724 79721871
Peak expiratory flow rate decreased 18.13 15.63 6 12787 677 79730918
Renal failure 17.95 15.63 5 12788 200963 79530632
General physical health deterioration 17.91 15.63 11 12782 275227 79456368
Autoimmune thyroiditis 17.58 15.63 10 12783 4223 79727372
Drug interaction 17.18 15.63 25 12768 415158 79316437
Vascular parkinsonism 17.08 15.63 4 12789 125 79731470
Immunoglobulins decreased 16.57 15.63 7 12786 1553 79730042
Sinus arrest 16.25 15.63 9 12784 3613 79727982
Blood thyroid stimulating hormone increased 16.15 15.63 13 12780 9695 79721900
Nail growth abnormal 15.71 15.63 5 12788 499 79731096

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC H03AA02 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
THYROID THERAPY
THYROID PREPARATIONS
Thyroid hormones
ATC H03AA03 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
THYROID THERAPY
THYROID PREPARATIONS
Thyroid hormones
FDA CS M0021977 Triiodothyronine
FDA EPC N0000175946 l-Triiodothyronine
CHEBI has role CHEBI:60311 thyroid hormones
CHEBI has role CHEBI:75771 Mus musculus metabolites
CHEBI has role CHEBI:77746 Homo sapiens metabolite

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Goiter indication 3716002 DOID:12176
Myxedema coma indication 21263006
Hypothyroidism indication 40930008 DOID:1459
Myxedema indication 43153006 DOID:11634
Congenital hypothyroidism indication 190268003 DOID:0050328
Simple goiter indication 267369002
Malignant tumor of thyroid gland indication 363478007 DOID:1781
T3 Suppression for Thyroid Function Test indication
Mild Hypothyroidism indication
Diagnostic Test for Thyroid Dysfunction indication
Myocardial infarction contraindication 22298006 DOID:5844
Thyrotoxic crisis contraindication 29028009 DOID:12837
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Osteoporosis contraindication 64859006 DOID:11476
Diabetes mellitus contraindication 73211009 DOID:9351
Hypopituitarism contraindication 74728003 DOID:9406
Angina pectoris contraindication 194828000
Osteopenia contraindication 312894000
Primary adrenocortical insufficiency contraindication 373662000
Disorder of coronary artery contraindication 414024009




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Dogs Hypothyroidism Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Cytobin Tablets Zoetis Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.08 acidic
pKa2 8.12 acidic
pKa3 8.77 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Thyroid hormone receptor alpha Nuclear hormone receptor AGONIST Kd 10.24 CHEMBL CHEMBL
Thyroid hormone receptor beta Nuclear hormone receptor AGONIST Ki 10.10 CHEMBL CHEMBL
Adenosine receptor A1 GPCR Ki 6.62 DRUG MATRIX
Cytochrome P450 2C9 Enzyme EC50 6.30 WOMBAT-PK
Prothrombin Enzyme EC50 8.92 CHEMBL
Peroxisome proliferator-activated receptor gamma Nuclear hormone receptor Kd 6.15 CHEMBL
Proliferating cell nuclear antigen Nuclear other IC50 5.44 CHEMBL
THAP domain-containing protein 1 Unclassified EC50 9 WOMBAT-PK
GABA-A receptor; anion channel Ion channel IC50 4.64 CHEMBL
Thyroid hormone receptor beta Transcription factor IC50 8.74 CHEMBL
GABA-A receptor; anion channel Ion channel EC50 5.15 CHEMBL

External reference:

IDSource
4022167 VUID
N0000020173 NUI
D01011 KEGG_DRUG
55-06-1 SECONDARY_CAS_RN
4018002 VANDF
4022167 VANDF
C0041014 UMLSCUI
CHEBI:18258 CHEBI
T3 PDB_CHEM_ID
CHEMBL1544 ChEMBL_ID
CHEMBL1201119 ChEMBL_ID
D014284 MESH_DESCRIPTOR_UI
DB00279 DRUGBANK_ID
2634 IUPHAR_LIGAND_ID
653 INN_ID
06LU7C9H1V UNII
5920 PUBCHEM_CID
10814 RXNORM
1964 MMSL
4982 MMSL
d00658 MMSL
002133 NDDF
004882 NDDF
126204001 SNOMEDCT_US
350358003 SNOMEDCT_US
61275002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0093-2178 TABLET 25 ug ORAL ANDA 26 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0093-2179 TABLET 5 ug ORAL ANDA 26 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0093-2180 TABLET 50 ug ORAL ANDA 26 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 16590-303 TABLET 50 1 ORAL ANDA 13 sections
Liothyronine sodium HUMAN PRESCRIPTION DRUG LABEL 1 16714-166 TABLET 5 ug ORAL ANDA 24 sections
Liothyronine sodium HUMAN PRESCRIPTION DRUG LABEL 1 16714-167 TABLET 25 ug ORAL ANDA 24 sections
Liothyronine sodium HUMAN PRESCRIPTION DRUG LABEL 1 16714-168 TABLET 50 ug ORAL ANDA 24 sections
Adthyza thyroid HUMAN PRESCRIPTION DRUG LABEL 2 24338-016 TABLET 2.25 ug ORAL Unapproved drug other 24 sections
Adthyza thyroid HUMAN PRESCRIPTION DRUG LABEL 2 24338-032 TABLET 4.50 ug ORAL Unapproved drug other 24 sections
Adthyza thyroid HUMAN PRESCRIPTION DRUG LABEL 2 24338-065 TABLET 9 ug ORAL Unapproved drug other 24 sections
Adthyza thyroid HUMAN PRESCRIPTION DRUG LABEL 2 24338-097 TABLET 13.50 ug ORAL Unapproved drug other 24 sections
Adthyza thyroid HUMAN PRESCRIPTION DRUG LABEL 2 24338-113 TABLET 18 ug ORAL Unapproved drug other 24 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 33261-964 TABLET 5 ug ORAL ANDA 25 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 39822-0151 INJECTION, SOLUTION 10 ug INTRAVENOUS ANDA 25 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 39822-0151 INJECTION, SOLUTION 10 ug INTRAVENOUS ANDA 25 sections
Triostat HUMAN PRESCRIPTION DRUG LABEL 1 42023-120 INJECTION 10 ug INTRAVENOUS NDA 25 sections
NP Thyroid 15 HUMAN PRESCRIPTION DRUG LABEL 2 42192-327 TABLET 2.25 ug ORAL unapproved drug other 23 sections
NP Thyroid 15 HUMAN PRESCRIPTION DRUG LABEL 2 42192-327 TABLET 2.25 ug ORAL unapproved drug other 23 sections
NP Thyroid 15 HUMAN PRESCRIPTION DRUG LABEL 2 42192-327 TABLET 2.25 ug ORAL unapproved drug other 23 sections
NP Thyroid 120 HUMAN PRESCRIPTION DRUG LABEL 2 42192-328 TABLET 18 ug ORAL unapproved drug other 23 sections
NP Thyroid 120 HUMAN PRESCRIPTION DRUG LABEL 2 42192-328 TABLET 18 ug ORAL unapproved drug other 23 sections
NP Thyroid 120 HUMAN PRESCRIPTION DRUG LABEL 2 42192-328 TABLET 18 ug ORAL unapproved drug other 23 sections
NP Thyroid 30 HUMAN PRESCRIPTION DRUG LABEL 2 42192-329 TABLET 4.50 ug ORAL unapproved drug other 23 sections
NP Thyroid 30 HUMAN PRESCRIPTION DRUG LABEL 2 42192-329 TABLET 4.50 ug ORAL unapproved drug other 23 sections
NP Thyroid 30 HUMAN PRESCRIPTION DRUG LABEL 2 42192-329 TABLET 4.50 ug ORAL unapproved drug other 23 sections
NP Thyroid 60 HUMAN PRESCRIPTION DRUG LABEL 2 42192-330 TABLET 9 ug ORAL unapproved drug other 23 sections
NP Thyroid 60 HUMAN PRESCRIPTION DRUG LABEL 2 42192-330 TABLET 9 ug ORAL unapproved drug other 23 sections
NP Thyroid 60 HUMAN PRESCRIPTION DRUG LABEL 2 42192-330 TABLET 9 ug ORAL unapproved drug other 23 sections
NP Thyroid 90 HUMAN PRESCRIPTION DRUG LABEL 2 42192-331 TABLET 13.50 ug ORAL unapproved drug other 23 sections
NP Thyroid 90 HUMAN PRESCRIPTION DRUG LABEL 2 42192-331 TABLET 13.50 ug ORAL unapproved drug other 23 sections